T-knife 治疗学,介绍其针对PRAME的TCR-T疗法数据,预计2026年进行临床试验。 T-knife Therapeutics to present data on its PRAME-targeted TCR-T therapy, with a clinical trial expected in 2026.

在2025年11月的SITC年会上,T-knife Therapeutics将在其针对PRAME的TCR-T疗法TK-6302上提交四项数据更新. T-knife Therapeutics will present four data updates on its PRAME-targeted TCR-T therapy TK-6302 at the SITC Annual Meeting in November 2025. 预测结果显示,在先进的固态肿瘤和TK-6302在模型中的安全性和有效性方面,PRAME的表达方式始终如一。 Preclinical results show consistent PRAME expression in advanced solid tumors and TK-6302’s safety and efficacy in models. 该疗法使用高度亲近的TCR、CD8核心受体和FAS开关受体,由捐助者和病人进行可缩放的制造。 The therapy uses a high-affinity TCR, CD8 coreceptor, and FAS switch receptor, with scalable manufacturing from donors and patients. 通过CRISPR编辑基因组显示了精确和安全性。 Genome editing via CRISPR shows precision and safety. MyTTM平台帮助识别新的肿瘤抗原。 The MyT™ platform aids in identifying new tumor antigens. 预计到2025年底将有临床试验申请,第一阶段试验计划于2026年进行。 A clinical trial application is expected by late 2025, with a Phase 1 trial planned for 2026.